Fig. 1 · Structure

Documents & Downloads

Tenovin-1

Cat. No. A11943 CAS 380315-80-0

p53 activator

Tenovin-1 is a small molecule activator of p53 transcriptional activity that protects against MDM2-mediated p53 degradation.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
p53
Mdm2

Tenovin-1 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Tenovin-1 from 4 published references. In vitro models include BL2 Burkitt's lymphoma cells expressing wild-type p53; U251.

Tenovin-1 In Vitro Studies

In BL2 Burkitt’s lymphoma cells expressing wild-type p53, treatment at 10 μM for 48 hr resulted in more than 75% cell death. Necrosis and apoptosis were measured by annexin-V/propidium iodide labeling and FACS. In U251 cells, treatment at 5 µM for 48 h increased nuclear size by 1.9-fold. The reported nuclear size was 2047.52 Arbitrary unit. In rat primary astrocytes, treatment at 4 μM for 24 h produced about 3 times more SA-β-gal-positive cells than the vehicle-treated astrocyte culture. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell Death in Burkitt’s Lymphoma Cells

Cell-based study · BL2 Burkitt's lymphoma cells expressing wild-type p53 [1]

In BL2 Burkitt’s lymphoma cells expressing wild-type p53, treatment at 10 μM for 48 hr resulted in more than 75% cell death. Necrosis and apoptosis were measured by annexin-V/propidium iodide labeling and FACS.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell death (necrosis and apoptosis) was measured by annexin-V/propidium iodide labeling and FACS.cell death more than 75% cell death[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
48 hr
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Tenovin-1

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Discovery and Characterization of Tenovin-1 (S10); Figure 1 legend (S147, S148)

Cell death (necrosis and apoptosis) was measured by annexin-V/propidium iodide labeling and FACS.: Cell death (necrosis and apoptosis) was measured by annexin-V/propidium iodide labeling and FACS.; comparator: DMSO (control) — Results > Discovery and Characterization of Tenovin-1 (S10); Figure 1 legend (S148)

Nuclear Enlargement in U251 Cells

Cell-based study · U251 [2]

In U251 cells, treatment at 5 µM for 48 h increased nuclear size by 1.9-fold. The reported nuclear size was 2047.52 Arbitrary unit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
size of the nucleusnuclear size 2047.52 Arbitrary unit[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM
Exposure duration
48 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Tenovin-1

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Nuclear size measurement (S11); RESULTS > Treatment with sirtuin inhibitors increased the nuclear size in glioblastoma cells (S29, S33); Figure 1 legend (S64, S65); Table I legend (S76); Table I (T1.h1, T1.r1)

size of the nucleus: size of the nucleus; comparator: DMSO (control) — RESULTS > Treatment with sirtuin inhibitors increased the nuclear size in glioblastoma cells (S33); Figure 1 legend (S65); Table I legend (S76); Table I (T1.h1, T1.r1)

SA-β-gal Positivity in Rat Primary Astrocytes

Cell-based study · Rat primary astrocytes [3]

In rat primary astrocytes, treatment at 4 μM for 24 h produced about 3 times more SA-β-gal-positive cells than the vehicle-treated astrocyte culture.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SA-β-gal-positive cell numberSA-β-gal-positive cell number about 3 times more SA-β-gal-positive cells[3]

Literature-Reported Treatment Conditions

Treatment concentration
4 μM
Exposure duration
24 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Tenovin-1

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Drug treatment (S12); MATERIALS AND METHODS > SA-β-gal staining (S16, S21); RESULTS > Determination of SA-β-gal-positive astrocytes in vitro (S47); Fig. 1. legend (S64, S68)

SA-β-gal-positive cell number: SA-β-gal-positive cell number; comparator: vehicle-treated astrocyte culture — RESULTS > Determination of SA-β-gal-positive astrocytes in vitro (S47); Fig. 1. legend (S68)

Tenovin-1 In Vivo Studies

Tenovin-1 was administered at 45 mg/kg body weight to male ZDF rats with hepatic fibrosis. The HFD group treated with Tenovin-1 had significantly lower body weight than HFD-fed rats after 21 weeks of HFD feeding. [4]

Body Weight in HFD-Fed ZDF Rats

Animal study · Male ZDF rats; hepatic fibrosis; n=6 [4]

Male ZDF rats with hepatic fibrosis received Tenovin-1 at 45 mg/kg body weight for 10 weeks after 10 weeks. The HFD group treated with Tenovin-1 had significantly lower body weight than HFD-fed rats after 21 weeks of HFD feeding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
body weightReported result The HFD group treated with Tenovin-1 had a significantly lower body weight than the HFD-fed rats after 21 weeks of HFD feeding[4]

Conditions shared by the study groups

Route
intraperitonially
Treatment course
After 10 weeks; Tenovin-1 administration for the next 10 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tenovin-1 45 mg/kg body weightHFD group fed with HFD dietThe HFD group treated with Tenovin-1 had a significantly lower body weight than the HFD-fed rats after 21 weeks of HFD feeding[4]
Tenovin-1 45 mg/kg body weight
Model: Male ZDF rats; hepatic fibrosis; n=6
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Tenovin-1

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Experimental model (S5, S11, S13, S14); Results > Tenovin-1 mitigates HFD-induced increase in body and liver weight along with histopathological changes in ZDF rats (S126)

body weight: body weight; comparator: HFD group fed with HFD diet — Results > Tenovin-1 mitigates HFD-induced increase in body and liver weight along with histopathological changes in ZDF rats (S126)

Tenovin-1 45 mg/kg body weight · Materials and Methods > Experimental model (S14); Results > Tenovin-1 mitigates HFD-induced increase in body and liver weight along with histopathological changes in ZDF rats (S126)

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 380315-80-0
Applications p53 activator
Formula C20H23N3O2S
Molecular Weight 369.5
SMILES
CC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC=C(C=C2)C(C)(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 65 mg/mL (175.92 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
14 mg/mL
Vehicle
15% Captisol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tenovin-1 Research References

  1. [1] Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008). PMID: 18455128 DOI: 10.1016/j.ccr.2008.03.004 Source material
  2. [2] Yoon KB, Park KR, Kim SY, et al. Induction of Nuclear Enlargement and Senescence by Sirtuin Inhibitors in Glioblastoma Cells. Immune Netw (2016). PMID: 27340387 DOI: 10.4110/in.2016.16.3.183 Source material
  3. [3] Bang M, Ryu O, Kim DG, et al. Tenovin-1 Induces Senescence and Decreases Wound-Healing Activity in Cultured Rat Primary Astrocytes. Biomol Ther (Seoul) (2019). PMID: 30092626 DOI: 10.4062/biomolther.2018.107 Source material
  4. [4] Sharma S, Gali S, Kundu A, et al. Tenovin-1, a Selective SIRT1/2 Inhibitor, Attenuates High-fat Diet-induced Hepatic Fibrosis via Inhibition of HSC Activation in ZDF Rats. Int J Biol Sci (2024). PMID: 38993557 DOI: 10.7150/ijbs.97304 Source material

Added to your cart

View Cart Checkout
Loading...